Pharma Firms Face China Trade Restrictions
The pharmaceutical industry is opposing proposed U.S. restrictions on investments in Chinese biotech and medical firms, warning that broad limits could disrupt global drug development and supply chains.
Industry resists sweeping investment bans
Pharmaceutical executives and lobbyists have met with lawmakers and administration officials in recent weeks to advocate for narrower rules. These discussions follow the Biden administration’s consideration of expanding restrictions on U.S. capital flowing into Chinese companies, particularly in biotechnology.
The proposed measures, part of a strategy to counter China’s technological and military advancements, could include bans on venture capital and private equity investments in Chinese firms working on advanced medical technologies. Industry groups caution that such restrictions might cut off access to critical manufacturing hubs, delay clinical trials, and slow the development of new treatments.
China plays a major role in global drug production, supplying active pharmaceutical ingredients (APIs) for many essential medicines. Disruptions in that supply chain could lead to shortages of antibiotics, pain relievers, and other widely used medications.
Related: Premiums Set to Rise Again
Some lawmakers argue that the risks of espionage and intellectual property theft justify stricter controls. Lobbying efforts have focused on separating legitimate medical research from technologies with potential military applications. Executives cite collaborations with Chinese firms on cancer treatments, rare disease therapies, and mRNA vaccine development as partnerships that should remain exempt. They also warn that broad bans could push Chinese companies to accelerate their own drug pipelines, increasing competition for U.S. firms.
Regulatory uncertainty looms
The Treasury Department plans to release draft rules later this year outlining which investments would be restricted. Delays have occurred partly due to industry pushback. Officials have indicated the final rules will likely target a narrower set of technologies, though specifics remain unclear.
The debate reflects a tension between economic interdependence and national security. The outcome could influence how quickly new drugs reach patients and who controls medical innovation.
The FDA continues reviewing applications for treatments with ties to China. Summit Therapeutics, a Massachusetts-based company, awaits a decision on its lung cancer drug ivonescimab, developed with a Chinese partner. The agency’s ruling, expected by mid-November, may set a precedent for how U.S. regulators handle drugs with significant foreign involvement.
